Search research articles
Contact Us
Filters
Showing results (181-190 of 249) with videos related to
Page
of 25
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2012
Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials
David Sibon, Marion Fournier, Josette Brière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2009
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
Georg Hess, Raoul Herbrecht, Jorge Romaguera, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 18, 2011
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study
Didier Decaudin, Nicolas Mounier, Hervé Tilly, et al.
Biomarker Research
|
October 4, 2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
Francine Foss, Bertrand Coiffier, Steven Horwitz, et al.
Cancer Treatment Reviews
|
September 10, 2014
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma
Bertrand Coiffier, Massimo Federico, Dolores Caballero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2013
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Vincent Ribrag, Jehan Dupuis, Herve Tilly, et al.
The Oncologist
|
October 10, 2013
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma
André Bosly, Andrew Grigg, Harald Holte, et al.
Blood
|
November 29, 2007
Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?
Alexandra Traverse-Glehen, Lucile Baseggio, Evelyne Callet- Bauchu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results
Franck Morschhauser, John P Leonard, Luis Fayad, et al.
Blood
|
November 16, 2007
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
Bertrand Coiffier, Stéphane Lepretre, Lars Møller Pedersen, et al.
Page
of 25
Search research articles
Search
Showing results (181-190 of 249) with videos related to
Sort By:
Page
of 25
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 10, 2012
Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials
David Sibon, Marion Fournier, Josette Brière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2009
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
Georg Hess, Raoul Herbrecht, Jorge Romaguera, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
May 18, 2011
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study
Didier Decaudin, Nicolas Mounier, Hervé Tilly, et al.
Biomarker Research
|
October 4, 2014
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
Francine Foss, Bertrand Coiffier, Steven Horwitz, et al.
Cancer Treatment Reviews
|
September 10, 2014
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma
Bertrand Coiffier, Massimo Federico, Dolores Caballero, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 18, 2013
A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Vincent Ribrag, Jehan Dupuis, Herve Tilly, et al.
The Oncologist
|
October 10, 2013
A randomized study of interferon α-2b versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma
André Bosly, Andrew Grigg, Harald Holte, et al.
Blood
|
November 29, 2007
Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?
Alexandra Traverse-Glehen, Lucile Baseggio, Evelyne Callet- Bauchu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2009
Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results
Franck Morschhauser, John P Leonard, Luis Fayad, et al.
Blood
|
November 16, 2007
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
Bertrand Coiffier, Stéphane Lepretre, Lars Møller Pedersen, et al.
Page
of 25